Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02440308 · ClinicalTrials.gov registry record · Phase 2
68Ga-DOTA-Bombesin PET/MRI in Imaging Patients With Prostate Cancer
A Phase 2 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT02440308: Completed Phase 2 study, sponsored by Stanford University.
NCT02440308 is a Phase 2 study that has completed, run by Stanford University. The registered enrollment target is 10 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02440308, a Phase 2 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
This clinical trial studies the use of gallium-68 (68Ga)-DOTA-Bombesin as the imaging agent for positron emission tomography (PET)/magnetic resonance imaging (MRI), collectively PET-MRI, in patients with prostate cancer. PET uses a radioactive substance called 68Ga-DOTA-Bombesin, which attaches to tumor cells with specific receptors on their surfaces. The PET scanner takes pictures that capture where the radioactive drug is "lighting up" and attaching to tumor cells, which may help doctors recognize differences between tumor and healthy prostate tissue. MRI uses radio waves and a magnet to make a picture of areas inside the body. Using 68Ga-DOTA-Bombesin in diagnostic procedures, such as PET/MRI, may allow doctors to identify smaller tumors than standard imaging.
Interventions
- PROCEDURE Positron Emission Tomography (PET) scan
- DRUG 68Ga-DOTA-Bombesin
- PROCEDURE Magnetic Resonance Imaging (MRI) scan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2015-04 |
| Est. Completion | 2015-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02440308
The ClinicalTrials.gov registry entry for NCT02440308 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Positron Emission Tomography (PET) scan is the first listed.
NCT02440308 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02440308 about?
NCT02440308 is a clinical study titled "68Ga-DOTA-Bombesin PET/MRI in Imaging Patients With Prostate Cancer". This clinical trial studies the use of gallium-68 (68Ga)-DOTA-Bombesin as the imaging agent for positron emission tomography (PET)/magnetic resonance imaging (MRI), collectively PET-MRI, in patients with prostate cancer. PET uses a radioactive substance called 68Ga-DOTA-Bombesin, which attaches to t...
What is the current status of trial NCT02440308?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2015-04. Estimated completion is 2015-06-30.
What interventions are being tested in trial NCT02440308?
The interventions under investigation include: Positron Emission Tomography (PET) scan (PROCEDURE), 68Ga-DOTA-Bombesin (DRUG), Magnetic Resonance Imaging (MRI) scan (PROCEDURE).
Who is sponsoring clinical trial NCT02440308?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.